Trial Profile
A first pilot, phase Ib study to evaluate the tolerability of nerve growth factor secreted by the NsG 0202 implantable biodelivery device in patients with Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs EC NGF (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Gloriana Therapeutics; NsGene
- 04 Nov 2008 NsG 0202 has successfully been implanted in six patients and in patients have been enrolled, according to a NsGene media release.
- 13 May 2008 New trial record.